TrialHaematologica2024

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Noemí Puig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.